Psychiatria Polska
October 31, 2022
Gniewko Więckiewicz, Dariusz Danel, Magdalena Piegza et al.
2 citations
MDMA is one of the most commonly used drugs in the world. Clinical studies are currently being conducted around the world on the use of this substance in the treatment of PTSD and alcoholism. However, little demographic information is available on users who use the substance for recreational purposes. The aim was to determine basic demographic and helath characteristics with validated tools....
Journal of Psychopharmacology
October 31, 2022
Grant Jones
28 citations
Background: Psychedelics are receiving renewed attention within Western medicine as they represent potential treatments for many difficult-to-treat mental health disorders. However, psychedelic science is limited in its focus and inclusion of racial and ethnic minorities. Hence, this study examines whether race and ethnicity moderate the associations that naturalistic...
Cureus
October 31, 2022
Arafath Mohamed, Shehla Touheed, Muzammil Ahmed et al.
11 citations
Post-traumatic stress disorder (PTSD) is a significant public health concern for which existing therapies are only marginally effective. Indisputably, the primary line of treatment for PTSD is psychotherapy, according to current treatment guidelines. However, PTSD continues to be a chronic condition even after psychotherapy, with high psychiatric and medical illness rates. There is a dire need...
October 27, 2022
Peder Clark
First patented by Merck in the early twentieth century, and reinvented by American chemists in the 1960s and 1970s, MDMA (3,4-methylenedioxymethamphetamine) has been characterised as a good-time party drug with a dark side. Ecstasy, ‘E’, ‘X’ or ‘molly’ is connected in contemporary parlance with EDM mega-raves and the sometimes lethal consequences of over-consumption. This chapter suggests that...
Frontiers in Psychiatry
October 26, 2022
Tor-Morten Kvam, Ivar W Goksøyr, Lowan H. Stewart et al.
11 citations
Background Major depressive disorder (MDD) is a world-leading cause of disability. The available treatments are not effective in all patients, and there is a significant need for more effective treatment options. Here we present the protocol for an investigator-initiated and publicly funded trial of MDMA-assisted therapy (MDMA-AT) for MDD. This single-site, open-label study investigates the...
Frontiers in Psychiatry
October 12, 2022
Robert J Sottile, Thomas Vida
30 citations
Post-traumatic stress disorder (PTSD) is a devastating psychiatric disorder afflicting millions of people around the world. Characterized by severe anxiety, intrusive thoughts, pervasive nightmares, an assortment of somatic symptoms, associations with severe long-term health problems, and an elevated risk of suicide, as much as 40–70% of patients suffer from refractory disease....
Journal of Psychoactive Drugs
October 11, 2022
Jeremy Weleff, Teddy J. Akiki, Brian S. Barnett
11 citations
Following a decades long period of investigational dormancy, there is renewed interest in employing psychedelics as psychiatric treatments. The academic journals, institutions, and countries that have helped sustain clinical psychedelic research and the evolution of the literature on clinical studies of psychedelics have only recently begun to be investigated. To expand upon this work, we...
October 10, 2022
Malcolm Hopwood
Therapy is turning to drugs previously known for being illicit party substances. But there’s no reason to abandon proper trials. A range of new therapies for mental illness were previously considered unthinkable — party drugs including ketamine, medicinal cannabis and psychedelics like MDMA, psilocybin and DMT. With mental health disorders a growing cause of disability […]
Frontiers in Psychiatry
October 10, 2022
Christopher S. Stauffer, Melanie Brown, Dee Adams et al.
40 citations
Introduction Transgender and gender diverse (TGD) people experience stigma, discrimination, trauma, and post-traumatic stress disorder (PTSD) at higher rates compared to the general population; however, TGD people have been underrepresented in PTSD research. Clinical trials of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy demonstrate promising safety and efficacy for the...
Scientific Reports
October 10, 2022
Grant Jones, Matthew K. Nock
46 citations
Psychedelic compounds have been linked to salutary mental health outcomes in both naturalistic and clinical settings; however, current research on psychedelics suffers from a lack of inclusion and focus on racial and ethnic minorities. Thus, the goal of our study was to assess whether race and ethnicity moderate the associations that naturalistic lifetime MDMA...
Religions
October 9, 2022
Nathan E. Fisher
13 citations
While the trait of absorption has received a considerable amount of scientific study, states of absorption have been comparatively understudied and even less scholarly or scientific attention has been paid to those that are cultivated within the contemplative traditions of Islam and Judaism. This paper explores canonical descriptions of states of contemplative absorption in Islamic and Jewish...
Journal of Psychoactive Drugs
October 5, 2022
Annie M. Mccartney, Hugh McGovern, Alexander de Foe
33 citations
Research on the therapeutic potential of psychedelic substances is expanding. A limitation within this field is the unpredictability of individual responses to psychedelics. Better understanding of factors predicting psychedelic experience is essential to clinical progress and wider harm reduction frameworks. Ketamine, MDMA, LSD and psilocybin were selected for comparison due to their promising...
Frontiers in Psychiatry
October 3, 2022
Jordi Camarasa, Pol Puigseslloses, Edurne Urquizu et al.
5 citations
The utility of classical drugs used to treat psychiatric disorders (e.g., antidepressants, anxiolytics) is often limited by issues of lack of efficacy, delayed onset of action or side effects. Psychoactive substances have a long history of being used as tools to alter consciousness and as a gateway to approach the unknown and the divinities. These substances were initially obtained from plants...
Cureus
October 2022
Nava R Sharma, Bharosa Sharma, Saral Lamichhane et al.
The recreational use of a drug such as 3,4-methylenedioxymethamphetamine (MDMA), also known as "ecstasy," may be associated with significant side effects. Although liver failure with ecstasy is rare, the use of the drug should be investigated in all patients with severe hepatitis of unknown origin. Early diagnosis and intervention can prevent patients from ending up in liver transplantation....
Pharmacology, Biochemistry, and Behavior
October 2022
Hayley N. Manke, Katharine H Nelson, Shihui Huang et al.
Polydrug use is well documented in synthetic cathinone users, although the consequences of such use are not well characterized. In pre-clinical research, a pre-exposure to a drug has been reported to attenuate the aversive effects of other drugs which has implications for their abuse potential. The goal of the present study was to investigate the impact of pre-exposure to the synthetic...
Journal of Psychopharmacology
October 1, 2022
Grant Jones, Jocelyn A. Ricard, Peter S. Hendricks et al.
7 citations
INTRODUCTION: 3,4-Methylenedioxymethamphetamine (MDMA/"ecstasy") is an empathogen that can give rise to increased pleasure and empathy and may effectively treat post-traumatic stress disorder. Although prior research has demonstrated associations between ecstasy use and favorable mental health outcomes, the associations between ecstasy and physical health have largely been unexplored. Thus, the...
Brain, Behavior, & Immunity - Health
October 1, 2022
S. Parekh, Lydia Adams, Gillian A. Barkell et al.
7 citations
Post-traumatic stress disorder (PTSD) is a devastating disorder that involves maladaptive changes in immune status. Using the stress-enhanced fear learning (SEFL) paradigm, an animal model of PTSD, our laboratory has demonstrated increased pro-inflammatory cytokine immunoreactivity in the hippocampus following severe stress. Recent clinical trials have demonstrated...
Neurotoxicity Research
October 1, 2022
Asieh Hosseini, Seyed Mohammad-Hossein Shetab-Boushehri, Seyed Vahid Shetab-Boushehri
3 citations
Methamphetamine (MA) and 3,4-methylenedioxymethamphetamine (MDMA) are empathogen (entactogen) psychoactive designer drugs which are mainly used for recreational purposes. Both MA and MDMA are central nervous system stimulants which are classified as monoamine neurotransmitter reuptake inhibitors. They have strong cytotoxic effects on dopaminergic and serotonergic neurons. Neurotoxicities of MA...
Otolaryngologic clinics of North America
October 1, 2022
Benjamin F Asher
As psychedelic medicine is becoming mainstream, physicians need to know something about these medications, their indications, contraindications, and potential for research. This article is a brief overview of the subject with some ideas of how psychedelic medicines can impact the practice of Otolaryngology-Head and Neck Surgery.
Current Psychiatry Reports
October 1, 2022
Gregory S. Barber, Scott T Aaronson
56 citations
Few treatments are available for patients with mood disorders or post-traumatic stress disorder (PTSD) who have already failed multiple interventions. After several decades when research into psychedelics was effectively halted by federal legislation, the past several years have shown the re-emergence of thoughtful investigations studying the utility of compounds such as...